AstraZeneca and Daiichi Sankyo are preparing regulatory filings that could make their HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the ...

Enhertu plus Perjeta showed significant improvement in progression-free survival in HER2-positive metastatic breast cancer patients compared to standard treatment. The DESTINY-Breast09 trial is the ...

But the companies said Monday that the planned interim analysis showed the drug, Enhertu, led to a “highly statistically significant and clinically meaningful improvement in progression-free ...

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line treatment in HER2-positive breast cancer after recording “highly ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of Enhertu (5.4mg/kg) either alone or in combination with pertuzumab versus standard of care ...

Topline results from a planned interim analysis of the DESTINY-Breast09 phase 3 trial showed Enhertu in combination with pertuzumab demonstrated a highly statistically significant and clinically ...

Get Instant Summarized Text (Gist) Trastuzumab deruxtecan, known as Enhertu, has been approved in the UK for treating advanced HER2-positive cancers that are inoperable or have metastasized. This ...

A new cancer drug called trastuzumab deruxtecan, also known as Enhertu, has just been approved in the UK. This drug is designed to help adults with certain types of advanced cancer that cannot be ...